Serum Proteomics on the Basis of Discovery of Predictive Biomarkers of Response to Androgen Deprivation Therapy in Advanced Prostate Cancer

Manish Kohli, Ann L Oberg, Douglas W. Mahoney, Shaun M. Riska, Robert Sherwood, Yuzi Zhang, Roman M. Zenka, Deepak Sahasrabudhe, Rui Qin, Sheng Zhang

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: We investigated the serum proteome of hormone-sensitive prostate cancer patients to determine candidate biomarkers associated with androgen deprivation therapy (ADT)efficacy. Patients and Methods: Serum proteomes generated using isobaric mass tags for relative and absolute quantitation were analyzed using reverse-phase liquid chromatography coupled to tandem mass spectrometry. The advanced hormone-sensitive prostate cancer cohorts studied were: (1)untreated “paired” pre-ADT and 4-month post-ADT hormone-sensitive patients (n = 15); (2)“early ADT failure” patients (n = 10)in whom ADT treatment failed within a short period of time; and (3)“late ADT failure” patients (n = 10)in whom ADT treatment failed after a prolonged response time. Differential abundance was assessed, and ingenuity pathway analysis (IPA)was used to identify interaction networks in selected candidates from these comparisons. Results: Between “post-ADT” and combined “early” and “late” ADT failure groups 149 differentially detected candidates were observed, and between “early” and “late” ADT failure groups 98 candidates were observed; 47 candidates were common in both comparisons. IPA network enrichment analysis of the 47 candidates identified 3 interaction networks (P <.01)including 17-β-estradiol, nuclear factor kappa-light-chain enhancer of activated B cells complex, and P38 mitogen-activated protein kinases as pathways with potential markers of response to ADT. Conclusion: A global proteomic analysis identified pathways with markers of ADT response, which will need validation in independent data sets.

Original languageEnglish (US)
JournalClinical Genitourinary Cancer
DOIs
StatePublished - Jan 1 2019

Fingerprint

Proteomics
Androgens
Prostatic Neoplasms
Biomarkers
Serum
Therapeutics
Hormones
Proteome
Group Psychotherapy
p38 Mitogen-Activated Protein Kinases
Reverse-Phase Chromatography
Tandem Mass Spectrometry
Reaction Time
Estradiol
B-Lymphocytes
Light

Keywords

  • Hormonal therapy
  • Predictive factors
  • Prostate cancer
  • Proteomics
  • Serum

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

Serum Proteomics on the Basis of Discovery of Predictive Biomarkers of Response to Androgen Deprivation Therapy in Advanced Prostate Cancer. / Kohli, Manish; Oberg, Ann L; Mahoney, Douglas W.; Riska, Shaun M.; Sherwood, Robert; Zhang, Yuzi; Zenka, Roman M.; Sahasrabudhe, Deepak; Qin, Rui; Zhang, Sheng.

In: Clinical Genitourinary Cancer, 01.01.2019.

Research output: Contribution to journalArticle

Kohli, Manish ; Oberg, Ann L ; Mahoney, Douglas W. ; Riska, Shaun M. ; Sherwood, Robert ; Zhang, Yuzi ; Zenka, Roman M. ; Sahasrabudhe, Deepak ; Qin, Rui ; Zhang, Sheng. / Serum Proteomics on the Basis of Discovery of Predictive Biomarkers of Response to Androgen Deprivation Therapy in Advanced Prostate Cancer. In: Clinical Genitourinary Cancer. 2019.
@article{4272109f02594e8a8247e13ccac99a65,
title = "Serum Proteomics on the Basis of Discovery of Predictive Biomarkers of Response to Androgen Deprivation Therapy in Advanced Prostate Cancer",
abstract = "Background: We investigated the serum proteome of hormone-sensitive prostate cancer patients to determine candidate biomarkers associated with androgen deprivation therapy (ADT)efficacy. Patients and Methods: Serum proteomes generated using isobaric mass tags for relative and absolute quantitation were analyzed using reverse-phase liquid chromatography coupled to tandem mass spectrometry. The advanced hormone-sensitive prostate cancer cohorts studied were: (1)untreated “paired” pre-ADT and 4-month post-ADT hormone-sensitive patients (n = 15); (2)“early ADT failure” patients (n = 10)in whom ADT treatment failed within a short period of time; and (3)“late ADT failure” patients (n = 10)in whom ADT treatment failed after a prolonged response time. Differential abundance was assessed, and ingenuity pathway analysis (IPA)was used to identify interaction networks in selected candidates from these comparisons. Results: Between “post-ADT” and combined “early” and “late” ADT failure groups 149 differentially detected candidates were observed, and between “early” and “late” ADT failure groups 98 candidates were observed; 47 candidates were common in both comparisons. IPA network enrichment analysis of the 47 candidates identified 3 interaction networks (P <.01)including 17-β-estradiol, nuclear factor kappa-light-chain enhancer of activated B cells complex, and P38 mitogen-activated protein kinases as pathways with potential markers of response to ADT. Conclusion: A global proteomic analysis identified pathways with markers of ADT response, which will need validation in independent data sets.",
keywords = "Hormonal therapy, Predictive factors, Prostate cancer, Proteomics, Serum",
author = "Manish Kohli and Oberg, {Ann L} and Mahoney, {Douglas W.} and Riska, {Shaun M.} and Robert Sherwood and Yuzi Zhang and Zenka, {Roman M.} and Deepak Sahasrabudhe and Rui Qin and Sheng Zhang",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.clgc.2019.03.006",
language = "English (US)",
journal = "Clinical Genitourinary Cancer",
issn = "1558-7673",
publisher = "Elsevier",

}

TY - JOUR

T1 - Serum Proteomics on the Basis of Discovery of Predictive Biomarkers of Response to Androgen Deprivation Therapy in Advanced Prostate Cancer

AU - Kohli, Manish

AU - Oberg, Ann L

AU - Mahoney, Douglas W.

AU - Riska, Shaun M.

AU - Sherwood, Robert

AU - Zhang, Yuzi

AU - Zenka, Roman M.

AU - Sahasrabudhe, Deepak

AU - Qin, Rui

AU - Zhang, Sheng

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background: We investigated the serum proteome of hormone-sensitive prostate cancer patients to determine candidate biomarkers associated with androgen deprivation therapy (ADT)efficacy. Patients and Methods: Serum proteomes generated using isobaric mass tags for relative and absolute quantitation were analyzed using reverse-phase liquid chromatography coupled to tandem mass spectrometry. The advanced hormone-sensitive prostate cancer cohorts studied were: (1)untreated “paired” pre-ADT and 4-month post-ADT hormone-sensitive patients (n = 15); (2)“early ADT failure” patients (n = 10)in whom ADT treatment failed within a short period of time; and (3)“late ADT failure” patients (n = 10)in whom ADT treatment failed after a prolonged response time. Differential abundance was assessed, and ingenuity pathway analysis (IPA)was used to identify interaction networks in selected candidates from these comparisons. Results: Between “post-ADT” and combined “early” and “late” ADT failure groups 149 differentially detected candidates were observed, and between “early” and “late” ADT failure groups 98 candidates were observed; 47 candidates were common in both comparisons. IPA network enrichment analysis of the 47 candidates identified 3 interaction networks (P <.01)including 17-β-estradiol, nuclear factor kappa-light-chain enhancer of activated B cells complex, and P38 mitogen-activated protein kinases as pathways with potential markers of response to ADT. Conclusion: A global proteomic analysis identified pathways with markers of ADT response, which will need validation in independent data sets.

AB - Background: We investigated the serum proteome of hormone-sensitive prostate cancer patients to determine candidate biomarkers associated with androgen deprivation therapy (ADT)efficacy. Patients and Methods: Serum proteomes generated using isobaric mass tags for relative and absolute quantitation were analyzed using reverse-phase liquid chromatography coupled to tandem mass spectrometry. The advanced hormone-sensitive prostate cancer cohorts studied were: (1)untreated “paired” pre-ADT and 4-month post-ADT hormone-sensitive patients (n = 15); (2)“early ADT failure” patients (n = 10)in whom ADT treatment failed within a short period of time; and (3)“late ADT failure” patients (n = 10)in whom ADT treatment failed after a prolonged response time. Differential abundance was assessed, and ingenuity pathway analysis (IPA)was used to identify interaction networks in selected candidates from these comparisons. Results: Between “post-ADT” and combined “early” and “late” ADT failure groups 149 differentially detected candidates were observed, and between “early” and “late” ADT failure groups 98 candidates were observed; 47 candidates were common in both comparisons. IPA network enrichment analysis of the 47 candidates identified 3 interaction networks (P <.01)including 17-β-estradiol, nuclear factor kappa-light-chain enhancer of activated B cells complex, and P38 mitogen-activated protein kinases as pathways with potential markers of response to ADT. Conclusion: A global proteomic analysis identified pathways with markers of ADT response, which will need validation in independent data sets.

KW - Hormonal therapy

KW - Predictive factors

KW - Prostate cancer

KW - Proteomics

KW - Serum

UR - http://www.scopus.com/inward/record.url?scp=85065519474&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065519474&partnerID=8YFLogxK

U2 - 10.1016/j.clgc.2019.03.006

DO - 10.1016/j.clgc.2019.03.006

M3 - Article

JO - Clinical Genitourinary Cancer

JF - Clinical Genitourinary Cancer

SN - 1558-7673

ER -